An estimated 35 million people in the US are affected by overactive bladder*1,2

Photograph of healthcare team having a meeting

OAB Overview Monograph

Overactive bladder (OAB) is a symptom complex that is generally not life-threatening yet compromising to everyday life.

Treatment Overview

OAB Treatment Monograph

Management of OAB may include a number of options that should be weighed against symptom severity and ADL factors.

* Estimates are based on 23% prevalence rate from the EpiLUTS study and 2018 US Census Bureau population number projections for 2018.

1. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087.
2. US Census Bureau. Age and Sex Composition: 2018. Available at: Sex&tid=ACSST1Y2018.S0101&hidePreview=false. Accessed November 4, 2020.

Tell us what interests you

How interested are you in learning more about the following topics?

The hypothetical role of targeted gene therapy in modulating BK channel expression
The role of beta-3 adrenergic receptor agonists in the treatment of patients with OAB
A comprehensive treatment overview for OAB
Treatment approaches in OAB
Recent publications on vibegron and OAB


We’ve received your completed survey. Thanks for participating.


Thank You.

We’ve received your inquiry. Thank you for contacting Urovant Sciences Medical Affairs. We will contact you shortly.


Take Survey

Welcome to
Urovant Sciences Medical Affairs

This site is intended as an educational resource for U.S. healthcare providers. The content may include information about products or potential uses that have not been approved by the U.S. Food and Drug Administration.

This information is not intended to be promotional or deliver medical advice.

Choose an option:

I’m a U.S. healthcare professional I’m a U.S. patient or caregiver